Compare KRO & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRO | ARQT |
|---|---|---|
| Founded | 1916 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.9M | 3.3B |
| IPO Year | 2004 | 2020 |
| Metric | KRO | ARQT |
|---|---|---|
| Price | $5.55 | $22.74 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.00 | ★ $34.00 |
| AVG Volume (30 Days) | 294.0K | ★ 1.2M |
| Earning Date | 03-09-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,859,400,000.00 | $376,072,000.00 |
| Revenue This Year | $3.47 | $34.46 |
| Revenue Next Year | $11.59 | $29.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $4.08 | $11.86 |
| 52 Week High | $7.94 | $31.77 |
| Indicator | KRO | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 39.50 |
| Support Level | $5.14 | $22.56 |
| Resistance Level | $5.85 | $27.26 |
| Average True Range (ATR) | 0.32 | 0.96 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 62.09 | 26.06 |
Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The majority of revenue comes from the United States.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.